Key Highlights
- The operating loss was USD 2.96 million, against USD 2.45 million.
- Total costs and expenses increased 20.5% to USD 2.98 million.
- Research and development costs were USD 846 thousand, against USD 607 thousand.
- The nine-month net loss was USD 9.95 million, against USD 9.78 million.
AIM ImmunoTech (NYSE American:AIM) reported a third quarter 2026 operating loss of USD 2.96 million, compared with USD 2.45 million in the third quarter of 2025. The company reported the figures in its quarterly filing for the period ended September 30, 2026.
Total costs and expenses increased 20.5% to USD 2.98 million from USD 2.47 million. Interest and other income was USD 74 thousand, compared with USD 3.05 million.
Operating Expenses
Research and development costs increased 39.4% to USD 846 thousand from USD 607 thousand. General and administrative costs were USD 2.13 million, compared with USD 1.80 million, an increase of 18.2%, which the filing attributes to increases in salaries and director fees.
For the nine months ended September 30, 2026, Research and Development costs were USD 1.92 million, compared with USD 2.86 million, and general and administrative costs were USD 6.83 million, compared with USD 5.83 million. Total costs and expenses were USD 8.77 million, compared with USD 8.78 million, and the operating loss was USD 8.70 million, compared with USD 8.71 million.
The net loss for the nine months was USD 9.95 million, compared with USD 9.78 million. The filing reports Depreciation and amortization of USD 852 thousand, compared with USD 559 thousand, in the cash flow statement, and a loss on investments of USD 3 thousand, compared with a gain of USD 17 thousand.
Ampligen Program
The filing states that Ampligen has not been approved by the FDA or marketed in the United States, but is approved for commercial sale in Argentina for the treatment of severe chronic fatigue syndrome. It states that, based on clinical success as to safety and efficacy in its pancreatic cancer early access program and an ongoing Phase 2 trial, the company has made the Business decision to focus its efforts on the development of Ampligen for the treatment of late-stage pancreatic cancer, which it believes can potentially lead to the most valuable path.
Going Concern
The filing states that, when substantial doubt about the company's ability to continue as a Going Concern exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt. It states that the conditions it describes raise substantial doubt regarding the company's ability to continue as a going concern for a period of at least one year from the date of issuance of the financial statements.
Cash and cash equivalents were USD 6.89 million at September 30, 2026, compared with USD 2.99 million at the prior Balance Sheet date, and marketable securities were USD 61 thousand, compared with USD 62 thousand. The net increase in cash and cash equivalents for the nine months was USD 3.90 million, compared with USD 646 thousand in the prior-year period.
AIM ImmunoTech Q3 2026 Earnings: Key Takeaways
AIM ImmunoTech reported a third quarter 2026 operating loss of USD 2.96 million and total costs and expenses of USD 2.98 million. The nine-month net loss was USD 9.95 million, and the filing includes a going concern disclosure.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...